Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A joke about creating a hair loss treatment in the kitchen, with replies encouraging more jokes.

The conversation discusses using Rogaine (Minoxidil) and ketoconazole for hair regrowth, with interest in trying a formulation with Azelaic Acid for potentially better results. Concerns about Azelaic Acid's effectiveness and safety, including skin sensitivity to sunburn, are mentioned.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The user's experience with Pyrilutamide for hair loss treatment, including their belief that it has sparked improvements in combination with other treatments such as Minoxidil and Finasteride. Another user was also hoping to see results from using Pyrilutamide alone.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The user has been using Actifolic Pyrilutamide 0.5% once daily for almost three weeks without noticing any side effects or progress. Other users suggest that significant results typically take 3-6 months to appear.